Erythropoietin production-promoting agent

• US 9,469,598 B2
• Filed: 10/05/2012
• Issued: 10/18/2016
• Est. Priority Date: 10/12/2011
• Status: Active Grant

• Current Assignee: Tohoku University National Universities Corporation
• Original Assignee: SBI Pharmaceuticals Co., Ltd. (Ajinomoto Co., Inc.), Tohoku University National Universities Corporation
• Inventors: Tanaka, Tohru, Nakajima, Motowo, Takahashi, Kiwamu, Abe, Takaaki
• Primary Examiner(s): TRAN, MY CHAU T
• Application Number:
  US14/350,522
• Publication Number:
  US 20140288172A1
• Time in Patent Office: 1,474 Days
• Field of Search: 514/502, 560/170, 562/567
• US Class Current: 1/1
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/221 with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/295 Iron group metal compounds
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C07C 217/08 the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom

Abstract

A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs.

Claims

1. A method for promoting production of erythropoietin, comprising:

administering to a subject with reduced erythropoietin production a therapeutically effective amount of a compound shown by the following Formula (I);

R¹—

NHCH₂COCH₂CH₂COOR² 

 

(I)

wherein R¹ represents a hydrogen atom, and R² represents a hydrogen atom, or a salt thereof.

2. A method for treating anemia arising from reduction of erythropoietin production, comprising:

administering to a subject with anemia arising from reduction of erythropoietin production an agent comprising a therapeutically effective amount of a compound shown by the following Formula (I);

R¹—

NHCH₂COCH₂CH₂COOR² 

 

(I)

wherein R¹ represents a hydrogen atom, and R² represents a hydrogen atom, or a salt thereof.

3. The method according to claim 2, characterized in that said agent further contains one or more metal-containing compounds.

4. The method according to claim 3, characterized in that said metal-containing compound is a compound containing a metal selected from the group consisting of iron, and zinc.

5. The method according to claim 3, characterized in that said metal compound is a compound containing iron.

6. The method according to claim 2 characterized in that said reduction of erythropoietin production is caused by inflammatory cytokine or uremic toxin.

7. The method according to claim 2, characterized in that said anemia is renal anemia.

8. The method according to claim 7, characterized in that said compound or a salt thereof promotes the production of erythropoietin.

9. The method according to claim 2, characterized in that said agent further contains one or more metal-containing compounds.

10. The method according to claim 2, characterized in that said anemia is renal anemia.

11. The method according to claim 3, characterized in that said anemia is renal anemia.

12. The method according to claim 4, characterized in that said anemia is renal anemia.

13. The method according to claim 5, characterized in that said anemia is renal anemia.

14. The method according to claim 6, characterized in that said anemia is renal anemia.